Unlearn’s strategy is to create digital copies, or virtual models, of clinical trial participants. Those digital twins take part in clinical trials just as human participants do. Humans and the digital copies are randomly assigned either the drug or placebo, and the digital copies forecast outcomes regardless of which one they receive. The approach allows trials to be done with fewer human participants, potentially saving time and money.